REGENERX Story

<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:4em;'>RB</div>
RGRX -- USA Stock  

USD 0.24  0.03  14.29%

As many rational traders are trying to avoid healthcare space, it makes sense to break down REGENERX BIOPHARMACEUTICALS a little further and understand how it stands against CSL and other similar entities. We are going to inspect some of the competitive aspects of both REGENERX and CSL.
Published over two weeks ago
View all stories for REGENERX BIOPHARMACEUTICA | View All Stories
Should we be acquiring CSL or REGENERX BIOPHARMACEUTICA?
By analyzing existing basic indicators between REGENERX BIOPHARMACEUTICA and CSL, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in CSL with a short position in REGENERX BIOPHARMACEUTICA. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. REGENERX BIOPHARMACEUTICA has an asset utilization ratio of 6.39 percent. This suggests that the company is making $0.0639 for each dollar of assets. An increasing asset utilization means that REGENERX BIOPHARMACEUTICALS is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as REGENERX or Novo Nordisk is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is REGENERX BIOPHARMACEUTICA's Liquidity

REGENERX BIOPHARMACEUTICA financial leverage refers to using borrowed capital as a funding source to finance REGENERX BIOPHARMACEUTICALS ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. REGENERX BIOPHARMACEUTICA financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between REGENERX BIOPHARMACEUTICA's total debt and its cash.

Correlation Between REGENERX and Novo Nordisk AS

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding REGENERX BIOPHARMACEUTICA together with similar or unrelated positions with a negative correlation. For example, you can also add Novo Nordisk to your portfolio. If Novo Nordisk is not perfectly correlated to REGENERX BIOPHARMACEUTICA it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When REGENERX BIOPHARMACEUTICA for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between RGRX and NVO for more information.

Bona fide gift to Allan Goldstein of 200000 shares of REGENERX BIOPHARMACEUTICA subject to Section 16

Legal trades by REGENERX BIOPHARMACEUTICA insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
REGENERX insider trading alert for gift of common stock by Allan Goldstein, the corporate stakeholder, on 8th of February 2021. This event was filed by Regenerx Biopharmaceutica with SEC on 2021-02-08. Annual statement of changes in beneficial ownership - SEC Form 5. Allan Goldstein currently serves as founder, chairman, chief scientific advisor and chairman of medical and scientific advisory board of REGENERX BIOPHARMACEUTICA [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now take a look at REGENERX BIOPHARMACEUTICA revenue. Based on the latest financial disclosure, REGENERX BIOPHARMACEUTICALS reported 76.76 K of revenue. This is 100.0% lower than that of the Healthcare sector and 99.99% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of REGENERX BIOPHARMACEUTICA. As for CSL we see revenue of 9.98 B, which is much higher than that of the Biotechnology

CSLLY
10 B
RGRX76,7607.16E-4
Sector742.91 Million6.93
CSLLY9.98 Billion93.07

Our take on REGENERX BIOPHARMACEUTICA to fall back

Current Information Ratio is up to -0.02. Price may slide again. REGENERX BIOPHARMACEUTICALS is displaying above-average volatility over the selected time horizon. Investors should scrutinize REGENERX BIOPHARMACEUTICALS independently to ensure intended market timing strategies are aligned with expectations about REGENERX BIOPHARMACEUTICA volatility. REGENERX BIOPHARMACEUTICALS is a potential penny stock. Although REGENERX BIOPHARMACEUTICA may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in REGENERX BIOPHARMACEUTICALS. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on REGENERX instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Takeaway

While many of the other players in the biotechnology industry are either recovering or due for a correction, REGENERX BIOPHARMACEUTICA may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 28th of March 2021, we believe REGENERX BIOPHARMACEUTICA is currently undervalued. It responds to the market and projects average odds of financial distress in the next two years. However, our primary 30 days Buy-Hold-Sell recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of REGENERX BIOPHARMACEUTICALS. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com